Overview

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.
Treatments:
Zolpidem